drugset
drugset / Trial / NCT04540627

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

NCT04540627 ↗

Phase 1 Completed 56 enrolled mAbxience Research S.L.
RandomizedParallel-groupTriple-blindOther

Summary

Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV).

Timeline

Start
2020-07-06
Primary completion
2020-10-23
Completion
2020-10-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Palivizumab Monoclonal antibody 8 mg/kg Intravenous
Comparator Palivizumab Monoclonal antibody 15 mg/kg Intravenous

Indications

No indication recorded.